Laddar populära aktier...
Redeye provides a research update following the Q3 report published by Lipum earlier today.
Redeye provides a research update following the Q2 report published by Lipum earlier today.
Redeye leaves a comment following Lipum’s announcement of further clinical advancements in the ongoing phase I study with lead candidate SOL...
Redeye provides a research update following the Q1 report published by Lipum earlier today.
Redeye leaves a short comment following Lipum’s announcement of a loan commitment of SEK20m with Flerie Invest.
Redeye provides a research update following Lipum’s clinical progress, recent rights issue, and revised development plan for SOL-116.
Redeye leaves a comment following the yesterday’s press release of the preliminary outcome of Lipum’s recent rights issue.
Redeye leaves a comment following Flerie Invest’s mandatory offer of SEK6.
Redeye provides a research update on Lipum following the Q4 report published by the company earlier today.
Redeye is encouraged to learn that Lipum’s lead candidate, SOL-116, has shown favorable safety and tolerability in the first part of the pha...
Redeye leaves a comment on today’s news that Einar Pontén is stepping down as the CEO of Lipum and that the Board has decided to appoint Ola...
Redeye provides a research update on Lipum following the Q3 report published by the company earlier today.
Redeye provides a research update on Lipum following the Q2 report published by the company earlier today.
Redeye leaves a comment following Lipum’s announcement of the preliminary outcome of the rights issue.
Redeye leaves a comment following Lipum’s announcement of an upcoming rights issue of up to 2,870,334 shares at a subscription price of SEK9...
Redeye provides a research update on Lipum following the Q1 report published by the company earlier today.
Redeye leaves a comment on the Q3 report published by Lipum earlier this morning.
Redeye leaves a comment following Lipum’s announcement of phase I trial initiation with SOL-116.
Redeye leaves a short comment following Lipum’s announcement yesterday regarding the outcome of the previously communicated directed share i...
Redeye leaves a short comment on Lipum’s announcement of a CTA approval for the phase I trial with SOL-116.
Redeye leaves a comment following Lipum’s announcement yesterday evening of a directed share issue of approximately SEK 39m.
Redeye leaves a comment on the Q2 report published by Lipum earlier this morning.
Redeye initiates coverage of Lipum, a Swedish biotech company offering a unique approach to the USD 60 billion-plus inflammatory diseases ma...
